JP Morgan Initiates Coverage On Immunome with Overweight Rating, Announces Price Target of $24
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng initiates coverage on Immunome (NASDAQ:IMNM) with an Overweight rating and a price target of $24.

April 30, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan initiated coverage on Immunome with an Overweight rating and set a price target of $24.
The initiation of coverage by JP Morgan with an Overweight rating and a price target significantly above the current trading price is likely to be viewed positively by the market. This endorsement from a major financial institution could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100